Stock Analysis, Dividends, Split History

JUNO / Juno Therapeutics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price86.96
Volume3,696,100.00
Market Cap ($M)10,096.52
Enterprise Value ($M)9,874.58
Book Value ($M)1,046.98
Book Value / Share9.02
Price / Book9.64
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Preferred Stock Shares Outstanding 0
Common Stock Shares Outstanding 114,313,000
Common Shares Outstanding 116,105,371
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.41
Return on Assets (ROA)-0.32
Return on Equity (ROE)-0.41
Balance Sheet (mrq) ($M)
Assets1,434.84
Liabilities387.85
Quick Ration/a
Current Ratio3.61
Income Statement (mra) ($M)
Revenues111,871,000.00
Operating Income-447.77
Net Income-437.11
Earnings Per Share Basic And Diluted-4.10
Cash Flow Statement (mra) ($M)
Cash From Operations-225.03
Cash from Investing-68.21
Cash from Financing-68.21
Identifiers and Descriptors
CUSIP48205A109
Central Index Key (CIK)1594864
Related CUSIPS
048205A10 48205A959 48205A909

Split History

Stock splits are used by Juno Therapeutics, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

REPH: Recro Pharma Analysis and Research Report

23h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

23h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

Related News Stories

Taking a Look at Trends in Biotherapeutics

2018-08-15 biospace
It’s not easy to predict trends in drugs, especially with breakthroughs in immunology and genetic engineering often causing dramatic changes in how biopharma companies approach new drugs. It was pretty obvious four or five years ago that early work in immuno-oncology was going to have a huge effect, and it did, when in 2017 the U.S. Food and Drug Administration (FDA) approved two chimeric antigen receptor (CAR) T-cell therapies, Gilead Sciences and Kite Pharma’s Yescarta (axicatagene ciloleucel) and Novartis’ Kymriah (tisagenlecleucel). (19-0)

One Year Later: Lessons Learned In CAR-T

2018-08-15 seekingalpha
Approaching the one-year anniversary of commercial CAR-T therapy, product sales remain in-line with expectations. Key determinants, including next-gen technology, healthcare policy, and new entrants will affect the competitive landscape. (9-0)

Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q2 2018 Results - Earnings Call Transcript

2018-08-07 seekingalpha
Welcome to the Fate Therapeutics Second Quarter 2018 Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being webcast live on the Investors & Media section of Fate webcast at fatetherapeutics.com. As a reminder, today's call is being recorded. (3-0)

6 Reasons Celgene Remains The Best Valued Large-Cap Pharma Stock

2018-08-02 seekingalpha
Celgene is beating revenue expectations for the first half of 2018 and has increased full-year guidance, yet the stock price remains deflated. (5-0)

Top Stock Reports for Celgene, Exxon Mobil & Berkshire Hathaway

2018-08-01 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Celgene (CELG), Exxon Mobil (XOM) and Berkshire Hathaway (BRK.B). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. (18-0)

Silicon Investor Message Boards

This table lists all message boards related to JUNO / Juno Therapeutics, Inc. on message board site Silicon Investor.

Juno Therapeutics Inc. (JUNO) Juno Therapeutics Inc. (JUNO) Juno Therapeutics Inc. (JUNO) JUNO JUNO JUNO
juno.com (JWEB)----IPO juno.com (JWEB)----IPO juno.com (JWEB)----IPO Juno.Com - Very Intresting Internet Co. Juno.Com - Very Intresting Internet Co. Juno.Com - Very Intresting Internet Co.
CUSIP: 48205A109